Road to Clinical Validation of NBE-002, a Novel PNU-anthracycline-based ROR1 Targeting iADC in Solid Tumours
Time: 9:20 am
day: Day Two
Details:
- Understand rationales for targeting ROR1 in solid tumour patients
- Analyse preliminary data from a phase I/IIa clinical study with NBE-002, a novel ROR1-targeting iADC
- Gain an overview of clinical study design and biomarker strategy for future efficacy studies, based on NBE-002’s mode of action
Speakers:
Ulf Grawunder is CEO of NBE-Therapeutics, a Swiss Biotech company that he founded in 2012 and which focuses on the development of “next-generation” antibody-drug conjugates for cancer therapy. Prior to that, Ulf had co-founded 4-Antibody in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and later as CSO, until the company was sold to US-based Agenus. Ulf is a Biochemist who did his PhD in the area of B cell Immunology at the Basel Institute for Immunology. After this he did several years of post-doctoral research at Washington University…Read more